Latest Ratios: P/E Ratio -3.2x · EV/EBITDA N/A · ROE -107.6%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $39M | $21M | $184M | $520M | $231M | $488M | $659M | $422M | $1.1B | $1.1B | $1.1B |
| Enterprise Value | $40M | $22M | $184M | $519M | $218M | $450M | $650M | $415M | $1.1B | $1.1B | $1.1B |
| P/E Ratio → | -3.24 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.01 | 1.64 | 10.29 | 28.45 | 17.92 | 43.37 | 74.16 | 30.33 | 100.50 | 154.73 | 78.18 |
| P/B Ratio | 4.27 | 2.32 | 14.52 | 41.25 | 9.09 | 13.10 | 148.56 | 62.10 | 417.47 | 53.19 | 170.22 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.75 | 10.26 | 28.37 | 16.91 | 39.97 | 73.15 | 29.83 | 100.26 | 151.90 | 77.47 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.5% | 53.5% | 53.1% | 49.7% | 48.1% | 60.0% | 57.1% | 48.6% | 38.0% | 28.1% | 20.7% |
| Operating Margin | -104.1% | -104.1% | -58.4% | -82.7% | -120.5% | -123.0% | -144.8% | -119.6% | -238.5% | -429.9% | -194.0% |
| Net Profit Margin | -91.4% | -91.4% | -63.2% | -83.1% | -116.8% | -86.8% | -178.2% | -87.2% | -238.2% | -396.1% | -165.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -107.6% | -107.6% | -89.5% | -79.9% | -48.1% | -46.9% | -281.8% | -254.7% | -223.8% | -208.6% | -306.0% |
| ROA | -50.0% | -50.0% | -40.8% | -43.5% | -33.5% | -28.0% | -74.4% | -61.3% | -97.0% | -93.3% | -82.9% |
| ROIC | -88.1% | -88.1% | -67.2% | -96.2% | -203.7% | — | — | — | -6385.0% | — | — |
| ROCE | -87.1% | -87.1% | -52.4% | -57.6% | -42.0% | -47.7% | -86.6% | -154.0% | -148.7% | -134.7% | -132.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.47 | 0.57 | 0.29 | 0.06 | 0.87 | 0.57 | 1.83 | 0.33 | 1.05 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.16 | -0.04 | -0.12 | -0.51 | -1.03 | -2.03 | -1.03 | -0.98 | -0.97 | -1.53 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -36.85 | -36.85 | -41.12 | -49.32 | -95.67 | -85.41 | -112.85 | -30.59 | -43.99 | -43.94 | -1465.88 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.63 | 1.63 | 2.50 | 2.49 | 3.37 | 6.97 | 3.70 | 2.40 | 1.48 | 3.81 | 3.28 |
| Quick Ratio | 1.07 | 1.07 | 1.89 | 1.87 | 2.81 | 6.65 | 3.31 | 2.08 | 1.14 | 3.48 | 3.03 |
| Cash Ratio | 0.14 | 0.14 | 0.86 | 1.06 | 2.23 | 5.89 | 2.59 | 1.39 | 0.76 | 3.03 | 2.67 |
| Asset Turnover | — | 0.64 | 0.67 | 0.63 | 0.32 | 0.23 | 0.43 | 0.64 | 0.64 | 0.19 | 0.58 |
| Inventory Turnover | 1.23 | 1.23 | 1.84 | 1.82 | 1.29 | 2.01 | 1.93 | 2.87 | 2.08 | 1.75 | 7.25 |
| Days Sales Outstanding | — | 208.41 | 147.38 | 112.72 | 130.74 | 151.31 | 139.27 | 136.59 | 117.89 | 137.01 | 45.69 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.6% | 1.1% | — | — | — | — | — | — | — | — | 0.9% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.6% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% |
| Shares Outstanding | — | $2M | $20M | $14M | $13M | $12M | $7M | $5M | $4M | $2M | $1M |
Imminent liquidity and solvency
Based on reported figures, Ekso's price-to-sales ratio of 4.21x appears disconnected from its 28.6% year-over-year revenue decline, suggesting that the market may be pricing in speculative acquisition potential rather than the company's current fundamental reality of persistent operating losses and a lack of positive earnings.
The absence of a meaningful P/E ratio and the reliance on P/S multiples highlight the speculative nature of the current valuation. Investors should monitor whether this premium persists if the company is forced to pursue dilutive financing to address its critically low cash reserves.
According to recent financial statements, Ekso's ROIC has remained deeply negative, reaching -50.9% in 2026Q1, which indicates that the company is failing to generate any economic return on its capital base and is instead actively destroying shareholder value through its current high-burn operational model.
The consistent negative trend in ROIC suggests that the company's R&D and SG&A investments are not translating into profitable growth. This structural inability to compound capital warrants significant caution, as it implies that additional investment may not yield the necessary returns to reach breakeven.
As reported in quarterly filings, the cash conversion cycle has ballooned to 499 days in 2026Q1, driven by excessive days inventory outstanding of 399 days, which suggests that the company is struggling to convert its specialized hardware inventory into cash within a reasonable timeframe.
The prolonged CCC indicates significant friction in the sales process and potential inventory obsolescence risks. This inefficiency ties up vital liquidity, exacerbating the company's already precarious cash position and limiting its operational flexibility in a challenging market environment.
Based on the company's reported figures, the current ratio of 1.55 and quick ratio of 1.03 in 2026Q1 provide a thin margin of safety, which is particularly concerning given the company's high cash burn rate and the potential for rapid depletion of its remaining liquid assets.
The reliance on inventory to meet current obligations, as evidenced by the gap between the current and quick ratios, leaves the firm vulnerable to liquidity shocks. Any further delay in product sales could quickly render the company unable to meet its short-term liabilities.
The price-to-book ratio of 5.97x is frequently misapplied to Ekso, as it obscures the fact that the company's book value is heavily comprised of intangible assets and R&D investments that may hold little liquidation value in the event of a sustained operational failure.
Investors should instead focus on the cash-to-burn ratio or the liquidity runway, as these metrics provide a more accurate assessment of the company's survival prospects. Relying on P/B in this context ignores the reality that the firm's primary assets are not easily monetizable.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EKSO stock.
Ekso Bionics Holdings, Inc.'s current P/E ratio is -3.2x. This places it at the 50th percentile of its historical range.
Ekso Bionics Holdings, Inc.'s return on equity (ROE) is -107.6%. The historical average is -165.3%.
Based on historical data, Ekso Bionics Holdings, Inc. is trading at a P/E of -3.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ekso Bionics Holdings, Inc.'s current dividend yield is 0.59%.
Ekso Bionics Holdings, Inc. has 53.5% gross margin and -104.1% operating margin.